Aclasta licence extended to include use in men

The licence for Aclasta (zoledronate) has been extended to include the treatment of osteoporosis in men at increased risk of fracture, including those with a recent low-trauma hip fracture.

The recommended dose for the treatment of postmenopausal osteoporosis and osteoporosis in men is a single 5mg intravenous infusion administered once a year.

View Aclasta drug record

Further information: Novartis

 

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

More from MIMS

Compare COVID-19 vaccines with new MIMS table

Compare COVID-19 vaccines with new MIMS table

Key characteristics of available COVID-19 vaccines...

Deleted products - live tracker

Deleted products - live tracker

EXCLUSIVE TO SUBSCRIBERS See the latest products removed...

Drug price changes - live tracker

Drug price changes - live tracker

EXCLUSIVE TO SUBSCRIBERS Use our constantly updated...

Drug shortages - live tracker

Drug shortages - live tracker

Use our constantly updated shortages tracker to check...